Deals channel feed – Endpoints News

Deals channel feed

Micro-cap Mei Pharma lands $100M upfront on beleaguered PI3K pathway

6 years ago

'Why not do it now?' Alnylam's John Maraganore takes up Blackstone's $2B offer to build the final 'bridge to profitability'

6 years ago

A bruised Circassia offloads debt by returning COPD drugs to AstraZeneca

6 years ago

Zai Lab finds latest target in Regeneron’s bispecific, paying up to $190M for Chinese rights

6 years ago

Roche makes a platform play, betting $190M in cash on Arrakis’ long-haul plans to drug RNA

6 years ago

Gilead gets in on the microbiome game with a $38M pact, up to $1.5B in milestones

6 years ago

Who's doing deals in the midst of a crippling pandemic? Here are the top 10 players for March

6 years ago

After putting aside a bitter legal feud, Alnylam and Dicerna chiefs make nice with an RNAi collaboration

6 years ago

GSK's Hal Barron buys a $250M stake in George Scangos' Vir and makes a beeline to the clinic with Covid-19 antibodies

6 years ago

Servier bags an antibody specialist in its latest oncology M&A deal with plans to add the platform tech

6 years ago

J&J gives pioneering stem cell biotech its first Big Pharma deal, partnering on iPSC CAR-T and CAR-NK

6 years ago

Novartis cancels $1B sale of generics after antitrust concerns forced delays

6 years ago

Daiichi Sankyo sinks $200M into new gene therapy tech from Ultragenyx

6 years ago

Eli Lilly antes up $60M gamble on a discovery deal with GSK-backed biotech

6 years ago

IL-6 to the rescue? Sanofi, Regeneron barrel ahead into another pivotal effort testing Kevzara for Covid-19

6 years ago

Pfizer, Mylan deal takes a coronavirus hit

6 years ago

Takeda antes up $44M for rare disease pact, turning to Oxford spinout's exosome tech

6 years ago

Roche forges deal with San Diego biotech, betting on new antibiotic class

6 years ago

Joining Novartis in siRNA space, AstraZeneca hands Silence $80M upfront for discovery deal

6 years ago

Astellas empowers newly energized CytomX with $80M upfront to get preclinical bispecific work going

6 years ago

Bayer inks up with “small” Indian biotech for new approach at an old target

6 years ago

Doing deals in a time of coronavirus: Biotech CEO Bill Haney says 'you focus on the things that make a difference'

6 years ago

GSK quietly reveals just how much cash they used to buy a chunk of the Bay Area's buzziest startup

6 years ago

TCR player Immatics combines with Perceptive’s blank check operator, scooping $252M and gaining a listing on Nasdaq

6 years ago

First page Previous page 92 93 949596 97 98 Next page Last page